KFMI(SZ:300666)2022-10-26 16:00Financial Performance - The company's revenue for Q3 2022 reached ¥599,007,940.84, representing a 49.72% increase compared to the same period last year[5]. - Net profit attributable to shareholders was ¥67,873,642.47, a significant increase of 96.06% year-over-year[5]. - The net profit after deducting non-recurring gains and losses was ¥72,641,214.96, reflecting a 153.88% increase compared to the previous year[5]. - The company reported a 50.01% increase in total revenue for the year-to-date, totaling ¥1,685,302,196.37[14]. - Total operating revenue for the period reached ¥1,685,302,196.37, a significant increase from ¥1,123,427,970.19 in the previous period, representing a growth of approximately 50%[56]. - Net profit attributable to shareholders of the parent company was ¥223,246,830.58, compared to ¥95,254,660.50 in the same period last year, marking an increase of about 134%[60]. - The company reported a comprehensive income total of ¥214,085,488.04, compared to ¥88,165,443.69 in the previous period, reflecting a growth of approximately 142.5%[60]. - The diluted earnings per share for the period was ¥0.96, compared to ¥0.44 in the previous period, representing a growth of about 118%[62]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥5,528,371,557.39, up 90.54% from the end of the previous year[5]. - The company's total equity rose to ¥3,651,472,346.17, up from ¥1,465,789,582.24, indicating a growth of around 148%[55]. - The total liabilities increased to ¥1,876,899,211.22 from ¥1,435,646,758.13, reflecting a growth of approximately 30.8%[54]. - The company's long-term equity investments increased to 205,909,086.51 RMB from 116,982,512.05 RMB, showing a growth of approximately 76%[49]. - The total number of shares held by major shareholders includes 4,574,523 shares held by Shanghai Zhidin Boneng Investment Partnership and 3,023,093 shares held by Shanghai Zhixing Bohui Investment Partnership, totaling 8,340,641 shares[26]. Cash Flow - Cash and cash equivalents reached ¥2,009,468,186.65, showing a substantial increase of 316.82% due to funds raised from issuing shares[13]. - The cash flow from financing activities saw a dramatic increase of 2,496.90% to ¥1,936,852,710.81, primarily due to the issuance of restricted stock and stock options[17]. - The cash flow from operating activities was not detailed in the provided data, but it is essential for assessing liquidity and operational efficiency[63]. - Net cash flow from operating activities was negative at CNY -24,162,946.66, compared to a positive CNY 104,646,698.68 in the prior period[64]. - Financing cash inflow surged to CNY 3,259,327,241.82, compared to CNY 1,546,814,314.34 in the previous period, marking a 110% increase[67]. - The ending cash and cash equivalents balance increased to CNY 2,002,946,777.00, compared to CNY 797,601,583.71 at the end of the previous period[67]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 24,074, with the largest shareholder holding 22.18%[18]. - As of the end of the reporting period, Mr. Yao Lijun's pledged shares amounted to 23,277,200 shares, with 705,882 new shares subscribed during the reporting period[27]. - The total number of restricted shares held by Mr. Yao Lijun at the end of the period is 42,764,051 shares, with no shares released from restriction during the reporting period[27]. - The company has a commitment that during Mr. Yao Lijun's tenure as a director, he can only transfer up to 25% of his total shares each year[27]. - The company has a policy that major shareholders must adhere to a 25% annual transfer limit on their shares during their tenure as directors or senior management[30]. Investment and Development - The company is actively involved in various investment partnerships, including those with Ningbo Haibang Talent Venture Capital Partnership and Ningbo Jiangfeng Biological Information Technology Co., Ltd.[26]. - The company plans to expand its market presence and enhance product development in the upcoming quarters[42]. - Research and development expenses for the period were ¥83,048,712.88, compared to ¥71,894,860.73 in the previous period, showing an increase of about 15.5%[60]. Stock Issuance - The company granted 3,106,000 restricted shares under the second equity incentive plan, which were listed on the Shenzhen Stock Exchange on March 18, 2022, with a 12-month lock-up period[33]. - The company issued 882,352 new shares to Jin Xin Fund Management Co., Ltd., with a lock-up period of 6 months starting from October 10, 2022, and these shares are expected to be released on April 10, 2023[33]. - The company issued 19,394,117 shares at a price of 85.00 RMB per share, raising a total of 1,648,499,945.00 RMB, with a net amount of 1,628,686,365.87 RMB after deducting issuance costs[40].